Skip to main navigation

Top Navigation

About Us
- Our Company
- Contact Us
Our Pipeline
- Pipeline
  - ZN-c5
  - ZN-c3
  - ZN-d5
  - ZN-e4
- Clinical Trials
Our Approach
- Integrated Discovery Engine
- Supporting Publications
Investors & Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Jun 28, 2021

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jun 28, 2021

Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated

May 28, 2021

Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference

May 17, 2021

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

Apr 12, 2021

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

Apr 10, 2021

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors

Mar 25, 2021

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

Mar 10, 2021

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021

Feb 25, 2021

Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities

Feb 24, 2021

Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 23

Investors/Media

Investor Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
- SEC Filings
Corporate Governance
Investor Resources

Investor Contact

Alexandra Roy
Solebury Trout
aroy@soleburytrout.com

Media Contact

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

“The sun is but a morning star.”

Corporate Office

530 Seventh Avenue
Suite 2201
New York, NY 10018

Science Center

10835 Road to the Cure
Suite 205
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com

Footer

Privacy Policy
Terms of Use
Site Map

Copyright © 2021 Zentalis Pharmaceuticals. All Rights Reserved.